Considering that p21 expression is typically downregulated by elevated levels of phosphorylated AKT, we postulated that a combinatorial therapeutic approach involving hERG activators and an AKT inhibitor MK-2206 might yield synergistic antitumor effects against breast cancer. The gene discussed is AKT1; the disease is breast carcinoma.